Jose L. Bello

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 21, 2021

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Journal: British journal of haematology

Published: September 14, 2018

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.

Journal: British journal of haematology

Published: July 01, 2018

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Journal: Blood

Published: August 13, 2017

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Journal: British journal of haematology

Published: February 06, 2017

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

Journal: Acta haematologica

Published: October 20, 2015

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Journal: Leukemia research reports

Published: June 03, 2015

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: September 28, 2014

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.

Journal: British journal of haematology

Published: March 14, 2014

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

Journal: Nuclear medicine communications

Published: July 25, 2013

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

Journal: Blood

Published: July 12, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026